long non-coding rna small nucleolar rna host gene 12 (SnHG12) has been demonstrated to be oncogenic. The aim of the present study was to examine the effects of SnHG12 on the progression of endometrial cancer (ec). The expression levels of SnHG12 and microrna (mir)-4429 were assessed in ec cell lines by reverse transcription-quantitative Pcr. Plasmids, including SnHG12 short hairpin rnas (shrnas), shrna negative control (nc), SnHG12 overexpression (oV), oV-nc, mir-4429 mimic and mimic-nc, were transfected into rl95-2 cells. Post-transfection, cell counting Kit-8, Transwell Matrigel and wound-healing assays were performed to assess cell proliferation, invasion and migration, respectively. cell cycle phase distribution was assessed by flow cytometry. The protein expression levels of matrix metalloproteinase (MMP)2 and MMP9 were detected by western blotting. mir-4429 target genes were predicted by bioinformatics analysis using target prediction online tools; the findings of this analysis were verified using a dual-luciferase reporter system. Identified as a target of miR-4429, SNHG12 was overexpressed in ec cell lines with decreased expression of mir-4429. Further experiments demonstrated that SnHG12 silencing and overexpression of mir-4429 markedly suppressed proliferation, migration and invasion of rl95-2 cells, arrested cells in the G 1 phase, and markedly downregulated the expression of MMP2 and MMP9. The opposite effects were observed in mir-4429 mimic-transfected rl95-2 cells after SNHG12 was overexpressed. The findings of the present study established the role of SnHG12 and mir-4429 in ec. Therefore, targeting the SnHG12/mir-4429 axis could serve as a potential future therapeutic target for treatment of ec.